Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 316

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial

Open access
Brunner, Hermine I, Ruperto, Nicolino, Zuber, Zbigniew, Keane, Caroline, Harari, Olivier, Kenwright, Andrew, Lu, Peng, Cuttica, Ruben, Keltsev, Vladimir, Xavier, Ricardo M, Calvo, Inmaculada, Nikishina, Irina, Rubio-Pérez, Nadina, Alexeeva, Ekaterina, Chasnyk, Vyacheslav, Horneff, Gerd, Opoka-Winiarska, Violetta, Quartier, Pierre, Silva, Clovis A, Silverman, Earl, Spindler, Alberto, Baildam, Eileen, Gámir, M Luz, Martin, Alan, Rietschel, Christoph, Siri, Daniel, Smolewska, Elzbieta, Lovell, Daniel, Martini, Alberto, De Benedetti, Fabrizio, Espada, Graciela, Allen, Roger, Chaitow, Jeffrey, Joos, Rik, Wouters, Carine, Knupp, Sheila, Sztajnbok, Flavio, Cabral, David, Houghton, Kristin, Roth, Johannes, Schmeling, Heinrike, Job-Deslandre, Chantal, Jorgensen, Christian, Paut, Isabelle Kone, Minden, Kirsten, Weller-Heinemann, Frank, Gerloni, Valeria, Zulian, Francesco, Burgos-Vargas, Ruben, Salazar, Carolina Duarte, Solis-Vallejo, Eunice, Calvo, Armando, Chavez, José, Zavaler, Manuel Ferrandiz, Gruenpeter, Anna, Kobusinska, Katarzyna, Sarychev, Alexey, Zholobova, Elena, Ramanan, Athimalaipet, Woo, Patricia, Goodman, Steven, Gedalia, Abraham, Kimura, Yukiko, Onel, Karen, Schikler, Kenneth · 2015 · Annals of the Rheumatic Diseases

Abstract

OBJECTIVE: To evaluate the interleukin-6 receptor inhibitor tocilizumab for the treatment of patients with polyarticular-course juvenile idiopathic arthritis (pcJIA). METHODS: This three-part, randomised, placebo-controlled, double-blind withdrawal study (NCT00988221) included patients who had active pcJIA for ≥6 months and inadequate responses to methotrexate. During part 1, patients received open-label tocilizumab every 4 weeks (8 or 10 mg/kg for body weight (BW) <30 kg; 8 mg/kg for BW ≥30 kg). At week 16, patients with ≥JIA-American College of Rheumatology (ACR) 30 improvement entered the 24-week, double-blind part 2 after randomisation 1:1 to placebo or tocilizumab (stratified by methotrexate and steroid background therapy) for evaluation of the primary end point: JIA flare, compared with week 16. Patients flaring or completing part 2 received open-label tocilizumab. RESULTS: In part 1, 188 patients received tocilizumab (<30 kg: 10 mg/kg (n=35) or 8 mg/kg (n=34); ≥30 kg: n=119). In part 2, 163 patients received tocilizumab (n=82) or placebo (n=81). JIA flare occurred in 48.1% of patients on placebo versus 25.6% continuing tocilizumab (difference in means adjusted for stratification: -0.21; 95% CI -0.35 to -0.08; p=0.0024). At the end of part 2, 64.6% and 45.1% of patients receiving tocilizumab had JIA-ACR70 and JIA-ACR90 responses, respectively. Rates/100 patient-years (PY) of adverse events (AEs) and serious AEs (SAEs) were 480 and 12.5, respectively; infections were the most common SAE (4.9/100 PY). CONCLUSIONS: Tocilizumab treatment results in significant improvement, maintained over time, of pcJIA signs and symptoms and has a safety profile consistent with that for adults with rheumatoid arthritis. TRIAL REGISTRATION NUMBER: NCT00988221.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2014-205351

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 316

Metadata

Authors
Brunner, H. I., Ruperto, N., Zuber, Z., Keane, C., Harari, O., Kenwright, A., Lu, P., Cuttica, R., Keltsev, V., Xavier, R. M., Calvo, I., Nikishina, I., Rubio-Pérez, N., Alexeeva, E., Chasnyk, V., Horneff, G., Opoka-Winiarska, V., Quartier, P., Silva, C. A., Silverman, E., Spindler, A., Baildam, E., Gámir, M. L., Martin, A., Rietschel, C., Siri, D., Smolewska, E., Lovell, D., Martini, A., De Benedetti, F., Espada, G., Allen, R., Chaitow, J., Joos, R., Wouters, C., Knupp, S., Sztajnbok, F., Cabral, D., Houghton, K., Roth, J., Schmeling, H., Job-Deslandre, C., Jorgensen, C., Paut, I. K., Minden, K., Weller-Heinemann, F., Gerloni, V., Zulian, F., Burgos-Vargas, R., Salazar, C. D., Solis-Vallejo, E., Calvo, A., Chavez, J., Zavaler, M. F., Gruenpeter, A., Kobusinska, K., Sarychev, A., Zholobova, E., Ramanan, A., Woo, P., Goodman, S., Gedalia, A., Kimura, Y., Onel, K., & Schikler, K.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2015-06
Volume
74
Issue
6
Pages
1110-1117
ISSN
0003-4967 (ISSN-L)
OpenAlex
W2110217426
Cited by
316
References
22
FWCI
18.57
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. https://app.cochat.ai/papers/10.1136/annrheumdis-2014-205351
The paper
Brunner, H. I., Ruperto, N., Zuber, Z., Keane, C., Harari, O., Kenwright, A., Lu, P., Cuttica, R., Keltsev, V., Xavier, R. M., Calvo, I., Nikishina, I., Rubio-Pérez, N., Alexeeva, E., Chasnyk, V., Horneff, G., Opoka-Winiarska, V., Quartier, P., Silva, C. A., . . . Schikler, K. (2015). Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2014-205351

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.